Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos de Nefrologia | EligiMed
Ensayos clinicos
349 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression
INTERVENTIONAL
Inicio: 8 de ago de 2023
ID: NCT05797610
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients
INTERVENTIONAL
Inicio: 11 de feb de 2014
ID: NCT02052310
Completado
Fase 3
ClinicalTrials.gov
Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
INTERVENTIONAL
Inicio: 27 de mar de 2013
ID: NCT01820572
Completado
Fase 3
ClinicalTrials.gov
An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00696384
Desconocido
ClinicalTrials.gov
Diagnosis of Monoclonal Gammopathy of Renal Significance in Patients With Paraproteinemias
OBSERVATIONAL
Inicio: 23 de feb de 2019
ID: NCT03629561
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)
INTERVENTIONAL
Inicio: 24 de abr de 2019
ID: NCT03888066
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease
INTERVENTIONAL
Inicio: 28 de feb de 2018
ID: NCT04036253
Completado
Fase 3
ClinicalTrials.gov
A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00622869
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
INTERVENTIONAL
Inicio: 17 de feb de 2014
ID: NCT02065791
Completado
Fase 3
ClinicalTrials.gov
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
INTERVENTIONAL
Inicio: 1 de may de 2011
ID: NCT01344460
Completado
Fase 2
ClinicalTrials.gov
An Extension to a 12-month, Open-label, Randomised, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients
INTERVENTIONAL
Inicio: 1 de sept de 2008
ID: NCT00820911
Completado
Fase 3
ClinicalTrials.gov
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00631371
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease
INTERVENTIONAL
Inicio: 21 de sept de 2021
ID: NCT05047263
Completado
ClinicalTrials.gov
A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
OBSERVATIONAL
Inicio: 1 de jun de 2011
ID: NCT01430494
Desconocido
ClinicalTrials.gov
Reduced Frequency Hemodialysis in Prevalent Patients Due to the Coronavirus Disease
OBSERVATIONAL
Inicio: 20 de mar de 2020
ID: NCT04374058
Completado
ClinicalTrials.gov
Development and Validation of a Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation
OBSERVATIONAL
Inicio: 1 de ene de 2004
ID: NCT04258891
Completado
Fase 2
ClinicalTrials.gov
A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to <18 Years With Chronic Kidney Disease on Dialysis
INTERVENTIONAL
Inicio: 15 de feb de 2013
ID: NCT01696279
Desconocido
ClinicalTrials.gov
Lupus Flares and Histological Renal Activity at the End of the Treatment
OBSERVATIONAL
Inicio: 1 de ene de 2014
ID: NCT02313974
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
INTERVENTIONAL
Inicio: 6 de jul de 2023
ID: NCT05852938
Completado
Fase 2
ClinicalTrials.gov
A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/Min/1.73 m^2
INTERVENTIONAL
Inicio: 28 de abr de 2021
ID: NCT04724837
Anterior
1
...
16
17
18
Siguiente
Filtros